Inhaled human insulin: An inspiration for patients with diabetes mellitus?

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 6, 2006, Pages 569-578

  Davidson, Michael B ^a   Mehta, Adi E ^a   Siraj, Elias S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LUNG DISEASE; LUNG FUNCTION TEST; MONOTHERAPY; NEBULIZER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; POWDER INHALER; RESPIRATORY TRACT INFECTION; REVIEW; SPIROMETRY; TREATMENT DURATION;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 33745085530     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.6.569     Document Type: Review

References (44)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
3. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27:1218-1224.
4. Brown JB, Nicholas GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999; 21:1045-1057.
5. Wigley F, Londono JH, Wood SH, Shipp JC, Waldman RH. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971; 20:552-556.
6. Laube B, Georgopoulos A, Adams GI. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269:2106-2109.
7. Laube B, Benedict G, Dobs A. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest 1998; 114:1734-1739.
8. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2:198-209.
9. Newhouse M. Tennis anyone? The lungs as a new court for systemic therapy. CMAJ 1999; 161:1287-1288.
10. Edwards D, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276:1868-1872.
11. Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aeroclose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003; 26:2842-2847.
12. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aeroclose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 25:2276-2281.
13. Rave K, Nosek L, Heinemann L, et al. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004; 21:763-768.
14. Rave KM, Nosek L, de la Pena A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005; 28:2400-2405.
15. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14:63-72.
16. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27:2356-2362.
17. Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004; 6:466-472.
18. Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110:17-21.
19. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28:1077-1082.
20. Jendle J, Karlberg B. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996; 240:93-98.
21. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000; 23:1343-1347.
22. Pfizer. Insulin Exubera US Package Insert, 2006.
23. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group. al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27:2622-2627.
24. Skyler JS, Weinstock RS, Raskin P, et al; Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28:1630-1635.
25. Cefalu WT, Skyler JS, Kourides IA, et al; Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134:203-207.
26. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27:162-167.
27. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005; 143:549-558.
28. DeFronzo RA, Bergenstal RM, Cefalu WT, et al; Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28:1922-1928.
29. Kohler D. Aerosols for systemic treatment. Lung 1990; 168(suppl):677-684.
30. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26:677-682.
31. Becker RHA, Sha S, Frick AD, Piechatzek R. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin (Exubera) [Abstract]. Diabetes 2003; 52:A37.
32. Department of Health and Human Services Food And Drug Administration Center for Drug Evaluation and Research Endocrinologic and Metabolic Drugs Advisory Committee. www.fda.gov/ohrms/dockets/ac/05/transcripts/ 2005-4169T1.pdf. Transcript of the meeting of Thursday, September 8, 2005.
33. Henry RR, Mudaliar SIR, Howland WC 3rd, et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003; 26:764-769.
34. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx Insulin Diabetes Management System. Br J Clin Pharmacol 2005; 59:546-551.
35. Leslie CC, McCormick-Shannon K, Robinson PC, Mason RJ. Stimulation of DNA synthesis in cultured rat alveolar type II cells. Exp Lung Res 1985; 8:53-66.
36. lida K, Suzuki H, Sone H, et al. Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway. Arterioscler Thromb Vasc Biol 2002; 22:380-386.
37. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357:331-335.
38. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH; Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163:2277-2282.
39. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90:3287-3294.
40. Heise T, Bott S, Tusek C, et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005; 28:2161-2169.
41. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24:1556-1559.
42. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24:552-564.
43. Cramer JA, Okikawa J, Bellaire S, Clauson P. Compliance with inhaled insulin treatment using the AERx iDMS Insulin Diabetes Management System. Diabetes Technol Ther 2004; 6:800-807.
44. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28:427-428.